Literature DB >> 21177811

Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.

Troels K H Scheel1, Judith M Gottwein, Thomas H R Carlsen, Yi-Ping Li, Tanja B Jensen, Ulrich Spengler, Nina Weis, Jens Bukh.   

Abstract

Hepatitis C virus (HCV) is an important cause of chronic liver disease, and interferon-based therapy cures only 40 to 80% of patients, depending on HCV genotype. Research was accelerated by genotype 2a (strain JFH1) infectious cell culture systems. We previously developed viable JFH1-based recombinants encoding the structural proteins (core, E1, E2), p7, and NS2 of prototype isolates of the seven major HCV genotypes; most recombinants required adaptive mutations. To enable genotype-, subtype-, and isolate-specific studies, we developed efficient core-NS2 recombinants from additional genotype 1a (HC-TN and DH6), 1b (DH1 and DH5), and 3a (DBN) isolates, using previously identified adaptive mutations. Introduction of mutations from isolates of the same subtype either led to immediate efficient virus production or accelerated culture adaptation. The DH6 and DH5 recombinants without introduced mutations did not adapt to culture. Universal adaptive effects of mutations in NS3 (Q1247L, I1312V, K1398Q, R1408W, and Q1496L) and NS5A (V2418L) were investigated for JFH1-based genotype 1 to 5 core-NS2 recombinants; several mutations conferred adaptation to H77C (1a), J4 (1b), S52 (3a), and SA13 (5a) but not to ED43 (4a). The mutations permitting robust virus production in Huh7.5 cells had no apparent effect on viral replication but allowed efficient assembly of intracellular infectious HCV for adapted novel or previously developed recombinants. In conclusion, previously identified mutations permitted development of novel HCV core-NS2 genotype recombinants. Mutations adapting several recombinants to culture were identified, but no mutations were universally adaptive across genotypes. This work provides tools for analysis of HCV genotype specificity and may promote the understanding of genotype-specific patterns in HCV disease and control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177811      PMCID: PMC3067958          DOI: 10.1128/JVI.01605-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.

Authors:  Jannick Prentoe; Tanja B Jensen; Philip Meuleman; Stéphanie B N Serre; Troels K H Scheel; Geert Leroux-Roels; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

2.  The importance of steatosis in chronic hepatitis C infection and its management: A review.

Authors:  Timothy J S Cross; Mohammed M Rashid; Philip A Berry; Phillip M Harrison
Journal:  Hepatol Res       Date:  2010-03       Impact factor: 4.288

3.  In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.

Authors:  Akito Sakai; Shingo Takikawa; Robert Thimme; Jean-Christophe Meunier; Hans Christian Spangenberg; Sugantha Govindarajan; Patrizia Farci; Suzanne U Emerson; Francis V Chisari; Robert H Purcell; Jens Bukh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

4.  Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient.

Authors:  T Kato; A Furusaka; M Miyamoto; T Date; K Yasui; J Hiramoto; K Nagayama; T Tanaka; T Wakita
Journal:  J Med Virol       Date:  2001-07       Impact factor: 2.327

5.  Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras.

Authors:  M Yanagi; R H Purcell; S U Emerson; J Bukh
Journal:  Virology       Date:  1999-09-15       Impact factor: 3.616

6.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Authors:  Troels K H Scheel; Judith M Gottwein; Tanja B Jensen; Jannick C Prentoe; Anne M Hoegh; Harvey J Alter; Jesper Eugen-Olsen; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

8.  Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly.

Authors:  Vlastimil Jirasko; Roland Montserret; Nicole Appel; Anne Janvier; Leah Eustachi; Christiane Brohm; Eike Steinmann; Thomas Pietschmann; Francois Penin; Ralf Bartenschlager
Journal:  J Biol Chem       Date:  2008-07-21       Impact factor: 5.157

9.  Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.

Authors:  Stephen Griffin; Corine Stgelais; Ania M Owsianka; Arvind H Patel; David Rowlands; Mark Harris
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

10.  NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly.

Authors:  Yinghong Ma; Jeremy Yates; Yuqiong Liang; Stanley M Lemon; MinKyung Yi
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

View more
  38 in total

1.  A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus.

Authors:  Daniel M Jones; Ali M Atoom; Xiaozhen Zhang; Shyamasundaran Kottilil; Rodney S Russell
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Authors:  Reema Wahdan-Alaswad; J Chuck Harrell; Zeying Fan; Susan M Edgerton; Bolin Liu; Ann D Thor
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Construction of a chimeric hepatitis C virus replicon based on a strain isolated from a chronic hepatitis C patient.

Authors:  Huang Cao; Wandi Zhu; Qingxia Han; Rongjuan Pei; Xinwen Chen
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

4.  Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.

Authors:  Yi-Ping Li; Santseharay Ramirez; Sanne B Jensen; Robert H Purcell; Judith M Gottwein; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

Review 5.  Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?

Authors:  Da-Rong Yang; Hai-Zhen Zhu
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

6.  Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.

Authors:  Laura Riva; Ok-Ryul Song; Jannick Prentoe; François Helle; Laurent L'homme; Charles-Henry Gattolliat; Alexandre Vandeputte; Lucie Fénéant; Sandrine Belouzard; Thomas F Baumert; Tarik Asselah; Jens Bukh; Priscille Brodin; Laurence Cocquerel; Yves Rouillé; Jean Dubuisson
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

7.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

8.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

9.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

10.  Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.

Authors:  Thomas H R Carlsen; Troels K H Scheel; Santseharay Ramirez; Steven K H Foung; Jens Bukh
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.